Featured Courses

Defining the therapeutic algorithm in patients with HR positive breast cancer - United States

Oncology

Course Description: At the end of this educational activity, you should have a clear picture of the latest clinical upda...

Antibody Drug Conjugates (ADC) - United States

Oncology

Course Description: This module is designed to offer healthcare professionals a thorough understanding of the wide range...

The Anti-seizure Medication Landscape and Their Effect on Non-seizure Symptoms

Neurology

Course Description: This module discusses the major anti-seizure medicines used for patients with DEEs and how they impa...

Advancements in ADC Therapy for Metastatic Triple Negative and HER+/HER2- Breast Cancer Treatment

Oncology

Course Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metast...

COURSES

ALL

Advancements in ADC Therapy for Metastatic Triple Negative and HER+/HER2- Breast Cancer Treatment

LAUNCH DATE: 23-Dec-2024

EXPIRATION DATE: 23-Dec-2025

Oncology

CREDITS

0.75 AMA PRA Category 1 Credit(s)™

Antibody Drug Conjugates (ADC) - United States

LAUNCH DATE: 11-Sep-2024

EXPIRATION DATE: 11-Sep-2025

Oncology

CREDITS

0.50 AMA PRA Category 1 Credit(s)™

0.50 ANCC Contact Hours

0.50 ACPE

0.50 Pharmacology

Collaborative Care with NSS (Non-Seizure Symptoms) in Mind

LAUNCH DATE: 30-Sep-2024

EXPIRATION DATE: 30-Sep-2025

Neurology

CREDITS

0.25 AMA PRA Category 1 Credit(s)™